Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab for MMR-deficient uterine cancer
NL-OMON58915Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in endometrial cancer (EC) and uterine cancer, sponsored by University Medical Center Groningen. Primary endpoint: Major pathologic response rate. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)uterine cancer
Beyond the preview
Go deeper on NL-OMON58915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58915.